BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 10731970)

  • 41. Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy.
    Capizzi RL; Scheffler BJ; Schein PS
    Cancer; 1993 Dec; 72(11 Suppl):3495-501. PubMed ID: 8242582
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Individualized cancer treatment. Illustrated by acute lymphoblastic leukemia in children].
    Schmiegelow K
    Ugeskr Laeger; 2001 Feb; 163(8):1062-6. PubMed ID: 11242663
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Cytoprotective effect of amifostine in children during induction therapy according to BFM-83: report on cases].
    Nowak K; Bolanowski W; Zalewska-Szewczyk B; Stolarska M; Bodalski J
    Wiad Lek; 1998; 51 Suppl 4():220-6. PubMed ID: 10731972
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin.
    Gallegos-Castorena S; Martínez-Avalos A; Mohar-Betancourt A; Guerrero-Avendaño G; Zapata-Tarrés M; Medina-Sansón A
    Pediatr Hematol Oncol; 2007 Sep; 24(6):403-8. PubMed ID: 17710657
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Accretion of bone mass in patients treated for childhood acute lymphoblastic leukemia].
    Muszyńska-Rosłan K; Konstantynowicz J; Krawczuk-Rybak M
    Pol Merkur Lekarski; 2007 Oct; 23(136):271-5. PubMed ID: 18293849
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Convulsions during treatment of acute lymphoblastic leukemia in children].
    Mainero G; Barisone E; Boffi P; Farinasso L; Landolfi C; Dalponte S; Sicca E; Papalla F; Miniero R; Madon E
    Minerva Pediatr; 2000 Apr; 52(4):205-14. PubMed ID: 11995204
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment of childhood acute lymphoblastic leukemia after the first relapse: curative strategies.
    Uderzo C; Dini G; Locatelli F; Miniero R; Tamaro P
    Haematologica; 2000 Nov; 85(11 Suppl):47-53. PubMed ID: 11268324
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Herpes zoster-associated morbidity in children undergoing chemotherapy for acute lymphoblastic leukaemia].
    Sørensen GV; Helgestad J; Rosthøj S
    Ugeskr Laeger; 2009 Nov; 171(46):3350-4. PubMed ID: 19925740
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Administration of Ethyol (amifostine) to a child with medulloblastoma to ameliorate hematological toxicity of high dose carboplatin.
    Borsi JD; Csaki C; Ferencz T; Oster W
    Anticancer Drugs; 1996 Jan; 7(1):121-6. PubMed ID: 8742109
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The need for cytoprotection.
    Bukowski RM
    Eur J Cancer; 1996; 32A Suppl 4():S2-4. PubMed ID: 8976815
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Radioprotectants: pharmacology and clinical applications of amifostine.
    Dorr RT
    Semin Radiat Oncol; 1998 Oct; 8(4 Suppl 1):10-3. PubMed ID: 9794995
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (Ethyol).
    Capizzi RL
    Eur J Cancer; 1996; 32A Suppl 4():S5-16. PubMed ID: 8976816
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Amifostine (Ethyol): dosing, administration and patient management guidelines.
    Bukowski RM
    Eur J Cancer; 1996; 32A Suppl 4():S46-9. PubMed ID: 8976823
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bone marrow purging by photodynamic treatment in children with acute leukemia: cytoprotective action of amifostine.
    Danilatou V; Lydaki E; Dimitriou H; Papazoglou T; Kalmanti M
    Leuk Res; 2000 May; 24(5):427-35. PubMed ID: 10785265
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical nanomedicine: a solution to the chemotherapy conundrum in pediatric leukemia therapy.
    Krishnan V; Rajasekaran AK
    Clin Pharmacol Ther; 2014 Feb; 95(2):168-78. PubMed ID: 24013811
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Amifostine: potential for clinically useful cytoprotection.
    Budd GT; Lorenzi V; Ganapathi R; Adelstein D; Pelley R; Olencki T; McLain D; Bukowski RM
    Support Care Cancer; 1994 Nov; 2(6):380-4. PubMed ID: 7858931
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Commentary: the pharmacological antioxidant amifostine -- implications of recent research for integrative cancer care.
    Block KI; Gyllenhaal C
    Integr Cancer Ther; 2005 Dec; 4(4):329-51. PubMed ID: 16465691
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Use of amifostine, a novel cytoprotective, in alpha-amanitin poisoning.
    Wills BK; Haller NA; Peter D; White LJ
    Clin Toxicol (Phila); 2005; 43(4):261-7. PubMed ID: 16035202
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Aggressive chemotherapy of ALL in elderly patients.
    Hoelzer D
    Hematol Oncol; 1993; 11 Suppl 1():12-4. PubMed ID: 8486336
    [No Abstract]   [Full Text] [Related]  

  • 60. [Acute leukemia: oral manifestations and treatment].
    Shubich I
    Pract Odontol; 1990 Sep; 11(9):21-2, 24, 26-7. PubMed ID: 2151940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.